165 related articles for article (PubMed ID: 22272435)
1. Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):265-6. PubMed ID: 22272435
[TBL] [Abstract][Full Text] [Related]
2. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
6. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
7. Statins in cardiometabolic disease: what makes pitavastatin different?
Ginsberg H
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
9. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Kakuda H; Matoba M; Nakatoh H; Nagao S; Takekoshi N
Scand J Clin Lab Invest; 2014 Jun; 74(4):285-95. PubMed ID: 24564634
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Chapman MJ; Le Goff W; Guerin M; Kontush A
Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
[TBL] [Abstract][Full Text] [Related]
11. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
Lim S; Park YM; Sakuma I; Koh KK
Int J Cardiol; 2013 Jun; 166(1):8-14. PubMed ID: 22503572
[TBL] [Abstract][Full Text] [Related]
12. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
13. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
Hausenloy DJ; Yellon DM
Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin and HDL: Effects on plasma levels and function(s).
Pirillo A; Catapano AL
Atheroscler Suppl; 2017 Jul; 27():e1-e9. PubMed ID: 28716185
[TBL] [Abstract][Full Text] [Related]
15. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
16. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
Teramoto T
Expert Opin Pharmacother; 2012 Apr; 13(6):859-65. PubMed ID: 22332608
[TBL] [Abstract][Full Text] [Related]
17. Controversies on HDL: should it be a target biomarker in patients with lipid disorders?
Nicholls SJ; Andrews J; Duong M
Curr Vasc Pharmacol; 2014; 12(4):649-52. PubMed ID: 23627977
[TBL] [Abstract][Full Text] [Related]
18. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
19. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
20. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
